I-O will be dominant drug class for liver cancer by 2029, says analyst

20 April 2021

Immuno-oncology (I-O) agents will be the dominant class in the hepatocellular carcinoma (HCC) market by 2029 due to the launch of pipeline drugs targeting programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).

These will constitute a large proportion of prescriptions as they will be used as monotherapy or in combinations through all stages and lines of therapy for HCC, a leading cause of liver cancer, says data and analytics company GlobalData.

Class-wide sales of I-O are expected to grow to 72.2% of the market, contributing $3.8 billion to global sales in 2029 and growing at a compound annual growth rate (CAGR) of 28%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK